Clenbuterol ( DrugBank: Clenbuterol )

4 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
1	球脊髄性筋萎縮症	1
2	筋萎縮性側索硬化症	1
6	パーキンソン病	2
256	筋型糖原病	2

1. 球脊髄性筋萎縮症

臨床試験数 : 17 / 薬物数 : 16 - (DrugBank : 8) / 標的遺伝子数 : 10 - 標的パスウェイ数 : 17

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2010-022558-18-IT (EUCTR)	11/10/2010	28/09/2012	A pilot trial with clenbuterol in spinal and bulbar muscular atrophy (SBMA).	A pilot trial with clenbuterol in spinal and bulbar muscular atrophy (SBMA).	spinal and bulbar muscular atrophy (SBMA) MedDRA version: 15.0;Level: HLGT;Classification code 10029317;Term: Neuromuscular disorders;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 15.0;Level: SOC;Classification code 10029205;Term: Nervous system disorders;Level: LLT;Classification code 10047868;Term: Weakness of limbs;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders MedDRA version: 15.0;Level: PT;Classification code 10013969;Term: Dyspnoea at rest;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: MONORES*30CPR 20MCG INN or Proposed INN: Clenbuterol	AZIENDA OSPEDALIERA DI PADOVA	NULL	Authorised-recruitment may be ongoing or finished			Female: no Male: yes			Italy

2. 筋萎縮性側索硬化症

臨床試験数 : 624 / 薬物数 : 611 - (DrugBank : 160) / 標的遺伝子数 : 172 - 標的パスウェイ数 : 225

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04245709 (ClinicalTrials.gov)	February 10, 2020	26/1/2020	Clenbuterol on Motor Function in Individuals With Amyotrophic Lateral Sclerosis	A Clinical Investigation of the Safety and Efficacy of Clenbuterol on Motor Function in Individuals With Amyotrophic Lateral Sclerosis	Amyotrophic Lateral Sclerosis	Drug: Clenbuterol	Dwight Koeberl, M.D., Ph.D.	NULL	Completed	18 Years	N/A	All	25	Phase 2	United States

6. パーキンソン病

臨床試験数 : 2,298 / 薬物数 : 2,202 - (DrugBank : 350) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2020-003796-17-GB (EUCTR)	22/10/2020	01/09/2020	A study to look at the effect of CST-103 or CST-139 on blood flow in the brain and on memory.	An Open-Label Brain Imaging and Cognition Study to Determine Changes in Cerebral Perfusion and Cognition After Oral Administration of CST-103 or CST-139	Patients with Mild Cognitive Impairment or Parkinson’s Disease MedDRA version: 21.1;Level: LLT;Classification code 10009846;Term: Cognitive impairment;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Spiropent Product Name: Clenbuterol HCl Product Code: CST-103 INN or Proposed INN: CLENBUTEROL HYDROCHLORIDE Trade Name: Berachin Product Name: Tulobuterol Product Code: CST-139 INN or Proposed INN: Tolubuterol Hydrochloride Other descriptive name: TULOBUTEROL HYDROCHLORIDE	CuraSen Therapeutics, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	32	Phase 2	United Kingdom
2	EUCTR2020-006067-28-BE (EUCTR)		18/11/2021	A study to investigate if CST-103 and CST-107 has an effect on the brain in patients with progressive disease of the nervous system.	A Phase II, Randomized, Placebo-Controlled, Double-Blind, Crossover, Study of the Pharmacodynamic Effects of CST-103 co-administered with CST-107 on the Central Nervous System in Subjects with Neurodegenerative Disorders - PD Effects of CST-103/CST-107 on CNS in Neurodegenerative Disorders	Patients with Parkinson’s Disease with REM sleep behaviour disorder, Mild Cognitive Impairment, Dementia with Lewy Bodies and Parkinson’s Disease Dementia. MedDRA version: 24.0;Level: LLT;Classification code 10012284;Term: Dementia due to Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 21.1;Classification code 10009846;Term: Cognitive impairment;Classification code 10067889;Term: Dementia with Lewy bodies;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Spiropent Product Name: Spiropent Product Code: CST-103 INN or Proposed INN: Clenbuterol Hydrochloride Product Name: Nadolol Product Code: CST-107 INN or Proposed INN: Nadolol	CuraSen Therapeutics, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	40	Phase 2	Belgium;Australia;United Kingdom;New Zealand

256. 筋型糖原病

臨床試験数 : 180 / 薬物数 : 153 - (DrugBank : 30) / 標的遺伝子数 : 31 - 標的パスウェイ数 : 134

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04094948 (ClinicalTrials.gov)	January 1, 2023	17/9/2019	Phase II Clinical Trial of Clenbuterol in Adult Patients With Pompe Disease	Phase II Clinical Trial of Clenbuterol in Adult Patients With Pompe Disease Stably Treated With Enzyme Replacement Therapy	Pompe Disease (Late-onset)	Drug: Clenbuterol;Drug: Placebos	Duke University	NULL	Not yet recruiting	18 Years	N/A	All	40	Phase 2	United States
2	NCT01942590 (ClinicalTrials.gov)	September 2013	11/9/2013	Safety and Efficacy of Clenbuterol in Individuals With Late-onset Pompe Disease and Receiving Enzyme Replacement Therapy	A Clinical Investigation of the Safety and Efficacy of Clenbuterol on Motor Function in Individuals With Late-onset Pompe Disease and Receiving Enzyme Replacement Therapy	Pompe Disease	Drug: Clenbuterol;Drug: Placebo	Dwight Koeberl, M.D., Ph.D.	NULL	Completed	18 Years	N/A	All	17	Phase 1/Phase 2	United States

先頭へ